Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
Tonix Pharmaceuticals presented promising data on their live virus vaccine platform at the Vaccine Congress 2024. Their TNX-801 vaccine demonstrated strong efficacy in protecting animals from lethal mpox (formerly monkeypox) challenges. TNX-801, designed for single-dose administration, offers long-term protection against mpox and smallpox. Additionally, their TNX-1800 vaccine for COVID-19 has been selected for clinical trials under NIH’s Project NextGen. The keynote highlighted the potential of these vaccines to address various infectious diseases effectively, with TNX-801 showing better tolerability compared to modern vaccines. The presentation also underscored the ongoing threat of mpox and the urgent need for advanced vaccines.
- TNX-801 demonstrated strong preclinical efficacy in protecting non-human primates from lethal mpox challenges.
- TNX-801 offers long-term protection with a single dose, providing an advantage over two-dose regimens.
- TNX-801 can be easily scaled for manufacturing and distributed without ultra-cold supply chains.
- TNX-1800 selected for clinical trials by NIH's Project NextGen, with NIH covering trial costs.
- TNX-801 shows improved tolerability compared to other orthopoxvirus-based vaccines.
- No concrete financial data or revenue projections provided.
- Potential risks of Clade I mpox becoming endemic in the U.S., which may require further vaccine developments.
Tonix Pharmaceuticals has introduced compelling preclinical data for their vaccine platform, highlighting its potential to combat mpox, smallpox and COVID-19. The efficacy of TNX-801, demonstrated in non-human primates, indicates promising protective capabilities against lethal mpox challenges, showcasing its potential in offering a resilient, single-dose solution. Single-dose vaccines are significant as they ensure greater compliance and ease of distribution, particularly in resource-limited settings. Furthermore, the inclusion of TNX-1800 in the NIH’s Project NextGen underscores its potential as a next-generation COVID-19 vaccine.
From an investor’s perspective, this development reflects positively on Tonix’s innovative approach and capability to address critical global health challenges. The robust preclinical results signify a step towards a diversified portfolio of vaccines targeting multiple infectious diseases. However, the jump from preclinical to clinical success is often fraught with challenges and investors should be mindful of the potential time and resource investment required to bring these vaccines to market.
Additionally, the ability to store these vaccines without an ultra-cold chain requirement is a notable competitive advantage, reducing logistical costs and complexities, which can be particularly beneficial in global health initiatives. While these are strong indicators of potential, the ultimate impact on the stock will depend on the outcomes of subsequent clinical trials and regulatory approvals.
The announcement positions Tonix Pharmaceuticals at the forefront of vaccine innovation with a potential market advantage due to their single-dose and more tolerable vaccine formulations. The market for mpox and smallpox vaccines is relatively niche but has gained prominence due to recent outbreaks and bioterrorism concerns. A single-dose vaccine could capture significant market share by offering convenience and lower administration costs.
Moreover, the involvement of the NIH’s Project NextGen in testing TNX-1800 provides external validation and may ease future regulatory hurdles. This could accelerate the time to market, offering Tonix a first-mover advantage in the next-generation COVID-19 vaccine space. However, investors should remain cautious about the competitive landscape, where established players with substantial resources may also be vying for market share.
The company’s readiness to scale up manufacturing and the simplified logistic requirements present further market opportunities, making it an attractive proposition for global health initiatives. However, the transition from preclinical to clinical phases and eventual market acceptance will be critical determinants of long-term stock performance.
Tonix’s live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose
TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with intratracheal monkeypox
Clade II mpox is now endemic in the U.S. with >30,000 cases reported since May 20221 and Clade I mpox is endemic in the Democratic Republic of the Congo2
Tonix’s vaccine platform has been selected by NIH’s Project NextGen for clinical testing
CHATHAM, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data presented at an oral Keynote Talk at the Vaccine Congress 2024 held June 24-25, 2024 in Prague, Czech Republic. A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.
The presentation titled, “A New Live Virus, One Dose Vaccine Platform for Mpox, Smallpox and COVID-19”, detailed the Company’s vaccine platform, including TNX-801 (horsepox, live virus) vaccine for preventing mpox (formerly known as monkeypox) and smallpox and TNX-1800 (horsepox expressing SARS-CoV-2 spike protein) for protecting against COVID-19. TNX-801 and TNX-1800 are live replicating attenuated vaccines based on horsepox that are believed to provide immune protection with better tolerability than modern vaccinia viruses. In the presentation, Tonix highlighted positive preclinical efficacy data, demonstrating that TNX-801 protected non-human primates against lethal challenge with intratracheal Clade 1 monkeypox virus3. After a single dose vaccination, TNX-801 prevented clinical disease and lesions and also decreased shedding in the mouth and lungs of non-human primates. These findings are consistent with mucosal immunity and suggest the ability to block forward transmission, similar to Dr. Edward Jenner’s vaccinia vaccine, which eradicated smallpox and kept mpox out of the human population.
“We are excited for the prospects of our live virus vaccine platform and look forward to advancing development for our vaccine candidates to prevent mpox, smallpox, COVID and other infectious diseases,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “TNX-801 combines immune protection with improved tolerability compared to other vaccines based on orthopoxviruses. TNX-801 is administered with a single dose which has advantages over two-dose regimens. We believe TNX-801 can be rapidly scaled up for manufacturing and can be distributed and stored without a costly and cumbersome ultra-cold supply chain. TNX-801 also has the potential to be used as a viral vector platform, for which recombinant versions can be developed to protect against other infectious diseases. Tonix developed TNX-1800 as a vaccine to protect against COVID-19. We are excited that TNX-1800 was selected for the U.S. National Institute of Health’s (NIH’s) Project NextGen and we look forward to providing updates on the program.”
The presentation noted that the global mpox outbreak, which commenced in 2022, has affected over 90,000 persons in countries where mpox had previously not been endemic, including Europe and the US. The spread of Clade IIb strain mpox in 2022 underscores the pandemic potential of mpox. Unlike Clade IIb mpox, the Clade I strain of mpox remains restricted to several Central African countries, including the Democratic Republic of the Congo, where it is currently endemic. Clade I mpox is typically associated with higher case fatality rates than Clade IIb mpox. According to the U.S. Centers for Disease Control and Prevention (CDC), and other experts, there is a significant risk that the deadlier Clade I strain may appear in the U.S.1,4.
Further, the presentation noted that the Bipartisan Commission on Biodefense recently highlighted the renewed dual threats of both a more virulent mpox epidemic as well as smallpox re-introduction from lab accidents or bad actors, while the National Academies of Science, in its review of smallpox preparedness, highlighted the need for new single dose vaccines against smallpox5,6.
The keynote presentation also included preclinical data for TNX-1800, demonstrating immunity and tolerability7,8. TNX-1800 was selected by the NIH’s Project NextGen for inclusion in clinical trials as part of a select group of next generation COVID-19 vaccine candidates with the intent to identify promising vaccine platforms. NIH plans to conduct a Phase 1 trial and cover the full cost, while Tonix provides the vaccine candidate.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya**, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.
**Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.
1McQuiston JH, et al. U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo. 2024, MMWR Morb Mortal Wkly Rep: United States. p. 435-440
2CDC. 2022-2023 Mpox: US Map and Case Count. https://www.cdc.gov/poxvirus/mpox/response/2022/us-map.html
3Noyce RS, et al. Viruses. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356. PMID: 36851570; PMCID: PMC9965234
4World Health OrganizationSAGE meeting highlights on updated mpox vaccine recommendations. 2024, March
5Bipartisan Commission on Biofence. Box the Pox: Redicing the risk of Smallpox and Other Orthopoxviruses, Washington:2024
6U.S. National Academies of Science. Future State of Smallpox Medical Countermeasures. Washington:2024
7Awasthi M, et al. Viruses. 2023 Oct 21;15(10):2131. doi: 10.3390/v15102131. PMID: 37896908; PMCID: PMC10612059.
8Awashti AM et al Vaccines (Basel). 2023 Nov 2;11(11):1682. doi:10.3390/vaccines11111682.PMID: 38006014
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182
Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505
Media Contact
Katie Dodge
LaVoieHealthScience
kdodge@lavoiehealthscience.com
(978) 360-3151
FAQ
What is TNX-801 by Tonix Pharmaceuticals?
How effective is TNX-801 in preclinical trials?
What is the significance of TNX-1800 being selected by NIH’s Project NextGen?
What are the advantages of TNX-801 over other vaccines?
Why is there a need for new vaccines against mpox and smallpox?
